Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients.

Trial Profile

Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Jan 2014

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 May 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 24 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 08 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top